tiprankstipranks
Advertisement
Advertisement

CNTX Stock Latest News

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
Company AnnouncementsContext Therapeutics Receives Nasdaq Minimum Bid Price Notice
2d ago
8K
CNTX
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
PremiumCompany Announcements
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
25d ago
CNTX
Context Therapeutics Shareholders Approve Stock Increase and Directors
PremiumCompany Announcements
Context Therapeutics Shareholders Approve Stock Increase and Directors
1M ago
8K
CNTX
Context Therapeutics price target lowered to $4 from $8 at Maxim
PremiumThe Fly
Context Therapeutics price target lowered to $4 from $8 at Maxim
2M ago
CNTX
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
PremiumRatings
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
2M ago
CNTX
Context Therapeutics selloff brings buying opportunity, says JonesResearch
PremiumThe FlyContext Therapeutics selloff brings buying opportunity, says JonesResearch
2M ago
CNTX
ZYME
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook
Premium
Ratings
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook
2M ago
CNTX
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
Premium
The Fly
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
2M ago
CNTX
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
PremiumCompany Announcements
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
2M ago
8K
CNTX
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
PremiumThe Fly
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
2M ago
CNTX
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
PremiumRatings
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
3M ago
CNTX
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
PremiumRatings
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
3M ago
CNTX
Context Therapeutics Secures Full Rights to Antibody Assets
PremiumCompany AnnouncementsContext Therapeutics Secures Full Rights to Antibody Assets
3M ago
8K
CNTX
Context Therapeutics enters license agreement amendment with BioAtla
Premium
The Fly
Context Therapeutics enters license agreement amendment with BioAtla
3M ago
BCAB
CNTX
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
Premium
Ratings
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
3M ago
CNTX
Context Therapeutics reports Q1 EPS (9c), consensus (12c)
PremiumThe Fly
Context Therapeutics reports Q1 EPS (9c), consensus (12c)
3M ago
CNTX
Context Therapeutics settles governance lawsuit with mootness fee
PremiumCompany Announcements
Context Therapeutics settles governance lawsuit with mootness fee
3M ago
8K
CNTX
Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
PremiumRatings
Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
3M ago
CNTX
Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating
PremiumRatings
Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating
3M ago
CNTX
Advancing Bispecific T‑Cell Engager Pipeline and Regulatory Milestones Underpin Buy Rating on Context
PremiumRatingsAdvancing Bispecific T‑Cell Engager Pipeline and Regulatory Milestones Underpin Buy Rating on Context
4M ago
CNTX
3 Best Stocks to Buy Today, 4/3/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 4/3/2026, According to Top Analysts
4M ago
AVNW
CNTX
Context Therapeutics Gains FDA Fast Track for CTIM-76
Premium
Company Announcements
Context Therapeutics Gains FDA Fast Track for CTIM-76
4M ago
8K
CNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >